Venous Thromboembolism in Acute Necrotizing Pancreatitis: A Nationwide Study of Clinical Outcomes and Healthcare Utilization

When the pancreas, a vital organ tucked behind the stomach, becomes severely inflamed and its tissue begins to die, the body enters a state of extreme crisis. This condition, known as acute necrotizing pancreatitis, triggers a massive internal storm. The body's immune system goes into overdrive, releasing a flood of chemicals that damage blood vessels and cause the blood to become thick and sticky, prone to forming clots. At the same time, the patient is often bedridden for weeks, hooked to machines, and unable to move, which slows the flow of blood in the legs and lungs. These factors combine to create a perfect environment for dangerous blood clots to form. These clots can block veins in the legs or travel to the lungs, a condition doctors call venous thromboembolism. While it is known that patients with this severe illness are at high risk for clots, it has remained unclear exactly how common these clots are, how they change the course of the disease, and whether they are the direct cause of death or simply a sign that a patient is already very sick.

To answer these questions, researchers examined a massive collection of hospital records from across the United States. They focused on over 20,000 adults who were admitted to the hospital in 2022 with acute necrotizing pancreatitis. The team sorted these patients into groups based on whether they developed blood clots, and if so, what kind: some had clots only in their legs, some had clots only in their lungs, some had both, and many had no clots at all. By comparing these groups, the researchers could see how the presence of a clot changed the patient's experience, from how long they stayed in the hospital to whether they survived.

The study revealed that blood clots are a frequent companion to this severe illness, appearing in roughly one out of every eight hospitalizations. Among those who developed clots, the vast majority had a blockage in a leg vein, while a smaller number had a blockage in the lung, and a tiny fraction had both. The difference in the hospital experience between those with clots and those without was stark. Patients with clots stayed in the hospital for significantly longer periods. Those with a clot in the lung alone stayed for an average of 38 days, and those with clots in both the lung and the leg stayed for nearly 46 days, compared to just 11.6 days for patients without clots. The financial cost followed the same pattern. The average hospital bill for a patient without a clot was about $158,000, but for those with clots in both the lung and the leg, the average bill soared to nearly $748,000.

Beyond the length of stay and the cost, the presence of a clot signaled a much more dangerous and complicated illness. Patients with clots were far more likely to develop severe infections, kidney failure, and respiratory failure requiring a breathing machine. They were also more likely to need intensive care unit-level support. The researchers found that the risk of bleeding was also higher in these patients, likely because treating the clots requires blood-thinning medication, which can be difficult to balance in a patient whose body is already struggling with severe inflammation and potential internal bleeding.

Perhaps the most surprising finding concerned the link between these clots and death. While patients with clots had much sicker courses and stayed in the hospital longer, the study found that the clot itself was not an independent cause of death once the severity of the patient's overall condition was taken into account. In other words, the blood clot was a marker of how critically ill the patient was, rather than the sole reason they died. The factors that actually drove the risk of death were things like the need for a breathing machine, septic shock, and kidney failure. Interestingly, patients who developed a clot only in their leg actually had a lower risk of dying in the hospital compared to those with no clots, a result the researchers suggest might be because these patients were monitored more closely or received earlier interventions.

However, the story changed when looking at what happened after the patient left the hospital. Patients who had developed a clot in their leg during their stay were more likely to be readmitted within 30 days. This suggests that the aftermath of the clot, or the underlying reasons it formed, continues to trouble patients even after they are discharged. The study did not find that clots in the lung alone were a strong predictor of readmission, possibly because the sample size for that specific group was smaller or because the severity of their illness kept them in the hospital longer.

This large-scale analysis paints a clear picture of the burden of blood clots in severe pancreatitis. It shows that while these clots are a common and costly complication that leads to longer hospital stays and more severe organ failure, they are often a sign of the body's extreme distress rather than the primary killer. The findings suggest that doctors need to pay very close attention to patients with this condition, not just to prevent clots, but to manage the complex balance of treating the clot while avoiding dangerous bleeding. The study concludes that better strategies are needed to identify which patients are at the highest risk and to tailor their care, ensuring that the fight against the clot does not come at the cost of other life-threatening complications.